Call for a post-doc position in the NCN research project SONATA-BIS9

Project’s title:
„Bioconjugates labeled with alpha- and beta-particle emitting radionuclides as potential radiopharmaceuticals in Targeted Radionuclide Therapy”

Project’s no:

Project’s PI:
dr hab. Marek Pruszyński, prof. ICHTJ

Job title:
post-doc in the project

Type of contract:
employment contract (full-time, 8 hours/day) for 24 months, with a salary of PLN 7,800 gross


  • PhD in chemistry, biology, biotechnology or related field (received up to 7 years before signing the employment contract under the project);
  • documented scientific achievements in the form of peer-reviewed articles in JRC journals;
  • fluent English, spoken and written, enabling efficient communication and preparation of scientific articles;
  • strong motivation for scientific work and assimilation of new knowledge and technical skills;
  • good interpersonal and communication skills, to be able to work in a multi-cultural environment both independently and as a part of a team.

Would be appreciated experience in the field of:

  • analytical methods (e.g. dialysis, HPLC);
  • cell culture and cellular research on monolayers and 3D-spheroids (e.g. toxicity or binding affinity of compounds etc.);
  • work with open radioactive sources.

Description of tasks:

  • participation in research work under the NCN SONATA-BIS9 – a short description of the project is presented below:
    “Cancer is the second leading cause of deaths in the world and its incidence steadily increases. Although incremental success have been achieved with more selective therapies targeting biomarkers typical for a cancer cell, still a large part of patients cannot be cured. Incomplete eradication of residual tumor cells and acquired drug resistance influence on relapse and progression of disease, especially in very aggressive and metastatic breast, ovarian and gastric cancers overexpressing HER2 receptor. Targeted radionuclide therapy (TRT) uses radionuclides attached to cancer-specific molecules to selectively deliver radiation to the tumor. The aim of this project is to develop novel radiobioconjugates based on anti-HER2 biomolecules labeled with α- and β-particle emitting radionuclides as potential new radiopharmaceuticals for TRT.”
  • participation in the preparation of bioconjugates based on biomolecules with attached chelating ligands such as: DOTA, DTPA, DFO etc., which then will be labeled with radioactive isotopes, e.g. Ac-225, Th-227, I-131, Y-90 etc.;
  • performing of in vitro cell assays, including: immunoreactivity, receptor binding affinity and specificity assays on tumor cells, cytotoxicity tests (e.g. cell proliferation, clonogenic assay, DNA double-strand break analysis), 3D cell culture etc.;
  • supervision over ongoing doctoral and master’s theses;
  • writing reports, publication and conference abstracts.

Deadline for submitting documents: 25 February 2024

The form of submitting documents: e-mail – please send documents to the Principal Investigator Marek Pruszyński, PhD, DSc: with the title of the email: “Call for a post-doc position in the project No 2019/34/E/ST4/00080”.

Required documents:

  • CV presenting the candidate’s scientific achievements and experience;
  • motivation letter;
  • reference letters (min. 1) from academic/professional referees;
  • a copy of the doctoral diploma.

Sending the recruitment documents is tantamount to consenting to the processing of personal data contained in the documentation by the Institute of Nuclear Chemistry and Technology in Warsaw in order to conduct the recruitment process. We inform you about the right to withdraw consent.